Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However, its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used pioneer models of myxoid/round cell liposarcoma (MRCLS) and undifferentiated pleomorphic sarcoma (UPS) developed from transformed human mesenchymal stromal/stem cells (MSCs) to evaluate the effect of trabectedin in the cell type responsible for initiating sarcomagenesis and their derived cancer stem cells (CSC) subpopulations.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ren1SW
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Point of view: Electrophysiological endpoints differ when comparing the mode of action of highly successful... Point of view: Electrophysiol...
-
Background Moyamoya angiopathy (MMA) is characterised by a progressive stenosis of the terminal part of the internal carotid arteries and th...
-
In view of the performance requirements (e.g., ride comfort, road holding, and suspension space limitation) for vehicle suspension systems, ...
-
Related Articles Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol:...
-
Abstract The core mission of the Early Stage Professionals in Molecular Imaging Sciences (ESPMIS) Interest Group is to help young scientist...
-
Abstract Background A reported penicillin allergy may compromise receipt of recommended antibiotic prophylaxis intended to prevent surgica...
-
Ravikiran N Pawar, Sambhunath Banerjee, Subhajit Bramha, Shekhar Krishnan, Arpita Bhattacharya, Vaskar Saha, Anupam Chakrapani, Saurabh Bhav...
-
Objectives A major measure of treatment success for drug users undergoing rehabilitation is the ability to enter the workforce and generate ...
-
Context. Despite improvement in pain management and availability of clinical treatment guidelines, patients in Jordan are still suffering fr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου